A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
Global COVID-19 cases surpassed 500 million on April 14, according to a Reuters tally, as the highly contagious BA.2 sub-variant of Omicron surges in many countries in Europe and Asia.
Pfizer Chief Executive Albert Bourla said on April 13 that the company could possibly develop a new vaccine that protects against the Omicron variant as well as older forms of COVID-19 by autumn.
The BA.2 Omicron subvariant of the coronavirus is responsible for 86% of U.S. COVID-19 cases and more than 90% of infections in the Northeast, according to data on April 12 from the U.S. Centers for Disease Control and Prevention (CDC).
RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV
Antibiotics, Antiretroviral Therapy, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID-19 Studies, COVID-19 treatment pill, Gilead, HIV, Hospitalized COVID-19 Patients, JAMA, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&D, Remdesivir, SteroidsAn experimental drug being developed by RedHill Biopharma Ltd. that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. Additionally, people living with well-controlled HIV infections are likely to have immune responses to the mRNA COVID-19 vaccines from Moderna and from Pfizer/BioNTech similar to those of otherwise healthy individuals, according to new data.
WHO analyzing two new Omicron COVID sub-variants
B.1.1.7 "Kent" strain (United Kingdom), B.1.1.7 Variant (UK), Coronavirus Disease 2019 (COVID-19), COVID-19 cases, COVID-19 Origins, COVID-19 recommendations, COVID-19 transmission, COVID-19 Variant B.1.1.7, Covid-19 Variants, Omicron (B.1.1.529) (South Africa), Omicron BA.2, R&DThe World Health Organization said on April 11 it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous.
Current COVID-19 vaccines are not well-matched against the BA.2 sub-variant of Omicron, the U.S. Food and Drug Administration said on April 6, as its panel of outside experts meets to discuss changes to future booster doses.
A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study in Israel found.
The U.S. health regulator said on April 5 GlaxoSmithKline and Vir Biotechnology’s antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.
The U.S. national public health agency said on April 4 the BA.2 sub-variant of Omicron was estimated to account for nearly three of every four coronavirus variants in the country.